<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869414</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00024168</org_study_id>
    <nct_id>NCT00869414</nct_id>
  </id_info>
  <brief_title>Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes</brief_title>
  <official_title>Comparison of Glycemic Response to Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes Using Continuous Glucose Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is a prospective, randomized, cross-over study that is being done to compare
      the effect of morning only, evening only and twice daily insulin glargine (LantusÂ®) on
      hypoglycemia (blood glucose level &lt;70 mg/dL) as measured by continuous glucose monitoring
      (CGM) in patients with type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over the course of the 6 week study, patients will take insulin glargine in each of 3
      different times: only in the morning, only at night, and half in the morning, half at night.
      After 2 weeks taking the insulin in one regimen, patients will be switched to another
      regimen. Through the whole study, patients will be injecting themselves twice daily, and
      neither the patient nor the treating doctor will know which vials contain the insulin and
      which have only saline (placebo). The vials will be labeled MORNING or EVENING. Patients will
      continue to take their mealtime, short acting insulin doses.

      Additionally, patients will wear a continuous glucose monitor (CGM) which will be masked.
      Before the study, patients will be taught about how to use the CGM, and keep it taped to
      their abdomen. The site that the CGM inserts into their abdomen will need to be changed every
      5 days. We will know if a patients' blood sugar goes low even if the patient did not feel the
      low. Patients will still have to self-monitor their blood sugar levels at-least four times in
      five days, to calibrate the CGM.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI deceased
  </why_stopped>
  <start_date type="Actual">July 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time Spent (Mean Number of Minutes Per 24 Hour Day) in Hypoglycemic Range (&lt;70mg/dl)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Mean Minutes Per 24 Hour Day in the Hyperglycemic Range of &gt; 180 mg/dL.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>insulin glargine only in morning</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morning only administration of insulin glargine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>insulin glargine only at evening</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evening only administration of insulin glargine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>split dose insulin glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Split dose administration of insulin glargine, half dose in morning, half dose in evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evening only administration of insulin glargine</intervention_name>
    <description>Evening only administration of insulin glargine, with normal saline injection administered in the morning.</description>
    <arm_group_label>insulin glargine only at evening</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morning only administration of insulin glargine</intervention_name>
    <description>Morning only administration of insulin glargine, with normal saline injection administered at night.</description>
    <arm_group_label>insulin glargine only in morning</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>split dose insulin glargine</intervention_name>
    <description>split dose of insulin glargine, half administered in the morning, half administered in evening</description>
    <arm_group_label>split dose insulin glargine</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men and women above age 18 with a diagnosis of type 1 diabetes mellitus

          -  On multiple insulin injections, including a long acting or intermediate acting insulin
             preparation and mealtime short acting insulin preparation.

          -  Clinical history consistent with hypoglycemia

          -  Hba1c &lt;9.0%

        Exclusion Criteria:

          -  Patients with type 2 diabetes mellitus

          -  Patients on insulin pump

          -  Poor control of diabetes (HbA1c &gt; 9.0%)

          -  Pregnancy (women of childbearing age will undergo a pregnancy test at the start of the
             study and will be advised to use birth control methods during the study). Insulin
             glargine has been reported to have teratogenic effects in animal models, and therefore
             should only be used during pregnancy if clearly needed.

          -  Serious co-morbidities that, in clinical opinion of the investigators, could affect
             pharmacokinetics of glargine (e.g., CRF) or safety (e.g., recent CAD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher D Saudek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ari S Eckman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Garg SK, Gottlieb PA, Hisatomi ME, D'Souza A, Walker AJ, Izuora KE, Chase HP. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract. 2004 Oct;66(1):49-56.</citation>
    <PMID>15364161</PMID>
  </reference>
  <reference>
    <citation>Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med. 2006 Aug;23(8):879-86.</citation>
    <PMID>16911626</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <results_first_submitted>April 13, 2017</results_first_submitted>
  <results_first_submitted_qc>May 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2017</results_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypoglycemia</keyword>
  <keyword>type 1 diabetes</keyword>
  <keyword>split dosing insulin glargine</keyword>
  <keyword>continuous glucose monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was prematurely terminated because the P.I. is deceased. Although 16 participants were enrolled, however, the number of participants starting and completing the study as well as the number of participants assigned to each Arm/Group are unknown, since no data are available</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Insulin Glargine Only in Morning</title>
          <description>Morning only administration of insulin glargine
Morning only administration of insulin glargine: Morning only administration of insulin glargine, with normal saline injection administered at night.</description>
        </group>
        <group group_id="P2">
          <title>Insulin Glargine Only at Evening</title>
          <description>Evening only administration of insulin glargine
Evening only administration of insulin glargine: Evening only administration of insulin glargine, with normal saline injection administered in the morning.</description>
        </group>
        <group group_id="P3">
          <title>Split Dose Insulin Glargine</title>
          <description>Split dose administration of insulin glargine, half dose in morning, half dose in evening
split dose insulin glargine: split dose of insulin glargine, half administered in the morning, half administered in evening</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This study was prematurely terminated because the PI is deceased. The Baseline data for the specific arms is unknown since no data are available. Only the baseline data for the overall population is available and reported.</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants were randomized to receive one of the three interventions: Insulin glargine only in the morning, Insulin glargine only in the evening, or a split dose of insulin glargine (half the dose in the morning and the other half in the evening).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age, &gt; 18 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time Spent (Mean Number of Minutes Per 24 Hour Day) in Hypoglycemic Range (&lt;70mg/dl)</title>
        <time_frame>6 weeks</time_frame>
        <population>This study was prematurely terminated because the P.I. is deceased. The data for the Outcome Measures (if collected) is unknown since no data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine Only in Morning</title>
            <description>Morning only administration of insulin glargine
Morning only administration of insulin glargine: Morning only administration of insulin glargine, with normal saline injection administered at night.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine Only at Evening</title>
            <description>Evening only administration of insulin glargine
Evening only administration of insulin glargine: Evening only administration of insulin glargine, with normal saline injection administered in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Split Dose Insulin Glargine</title>
            <description>Split dose administration of insulin glargine, half dose in morning, half dose in evening
split dose insulin glargine: split dose of insulin glargine, half administered in the morning, half administered in evening</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent (Mean Number of Minutes Per 24 Hour Day) in Hypoglycemic Range (&lt;70mg/dl)</title>
          <population>This study was prematurely terminated because the P.I. is deceased. The data for the Outcome Measures (if collected) is unknown since no data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in the Mean Minutes Per 24 Hour Day in the Hyperglycemic Range of &gt; 180 mg/dL.</title>
        <time_frame>6 weeks</time_frame>
        <population>This study was prematurely terminated because the P.I. is deceased. The data for the Outcome Measures (if collected) is unknown since no data are available</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine Only in Morning</title>
            <description>Morning only administration of insulin glargine
Morning only administration of insulin glargine: Morning only administration of insulin glargine, with normal saline injection administered at night.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine Only at Evening</title>
            <description>Evening only administration of insulin glargine
Evening only administration of insulin glargine: Evening only administration of insulin glargine, with normal saline injection administered in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Split Dose Insulin Glargine</title>
            <description>Split dose administration of insulin glargine, half dose in morning, half dose in evening
split dose insulin glargine: split dose of insulin glargine, half administered in the morning, half administered in evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Mean Minutes Per 24 Hour Day in the Hyperglycemic Range of &gt; 180 mg/dL.</title>
          <population>This study was prematurely terminated because the P.I. is deceased. The data for the Outcome Measures (if collected) is unknown since no data are available</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This study was prematurely terminated because the P.I. is deceased. The time frame for Adverse Event data (if collected) is unknown since no data are available.</time_frame>
      <desc>This study was prematurely terminated because the P.I. is deceased. The data for the Adverse Events (if collected) is unknown since no data are available.</desc>
      <group_list>
        <group group_id="E1">
          <title>Insulin Glargine Only in Morning</title>
          <description>Morning only administration of insulin glargine
Morning only administration of insulin glargine: Morning only administration of insulin glargine, with normal saline injection administered at night.</description>
        </group>
        <group group_id="E2">
          <title>Insulin Glargine Only at Evening</title>
          <description>Evening only administration of insulin glargine
Evening only administration of insulin glargine: Evening only administration of insulin glargine, with normal saline injection administered in the morning.</description>
        </group>
        <group group_id="E3">
          <title>Split Dose Insulin Glargine</title>
          <description>Split dose administration of insulin glargine, half dose in morning, half dose in evening
split dose insulin glargine: split dose of insulin glargine, half administered in the morning, half administered in evening</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Johns Hopkins University Clinical Trials Program</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-550-6484</phone>
      <email>registerclinicaltrials@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

